Literature DB >> 24332856

An optimized microRNA backbone for effective single-copy RNAi.

Christof Fellmann1, Thomas Hoffmann2, Vaishali Sridhar3, Barbara Hopfgartner2, Matthias Muhar2, Mareike Roth2, Dan Yu Lai3, Inês A M Barbosa2, Jung Shick Kwon3, Yuanzhe Guan3, Nishi Sinha3, Johannes Zuber4.   

Abstract

Short hairpin RNA (shRNA) technology enables stable and regulated gene repression. For establishing experimentally versatile RNAi tools and minimizing toxicities, synthetic shRNAs can be embedded into endogenous microRNA contexts. However, due to our incomplete understanding of microRNA biogenesis, such "shRNAmirs" often fail to trigger potent knockdown, especially when expressed from a single genomic copy. Following recent advances in design of synthetic shRNAmir stems, here we take a systematic approach to optimize the experimental miR-30 backbone. Among several favorable features, we identify a conserved element 3' of the basal stem as critically required for optimal shRNAmir processing and implement it in an optimized backbone termed "miR-E", which strongly increases mature shRNA levels and knockdown efficacy. Existing miR-30 reagents can be easily converted to miR-E, and its combination with up-to-date design rules establishes a validated and accessible platform for generating effective single-copy shRNA libraries that will facilitate the functional annotation of the genome.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24332856     DOI: 10.1016/j.celrep.2013.11.020

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  296 in total

1.  Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Authors:  Lan Cao; Ahmed Basudan; Matthew J Sikora; Amir Bahreini; Nilgun Tasdemir; Kevin M Levine; Rachel C Jankowitz; Priscilla F McAuliffe; David Dabbs; Sue Haupt; Ygal Haupt; Peter C Lucas; Adrian V Lee; Steffi Oesterreich; Jennifer M Atkinson
Journal:  Cancer Lett       Date:  2019-06-20       Impact factor: 8.679

2.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

3.  ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Authors:  Rohit Bose; Wouter R Karthaus; Joshua Armenia; Wassim Abida; Phillip J Iaquinta; Zeda Zhang; John Wongvipat; Elizabeth V Wasmuth; Neel Shah; Patrick S Sullivan; Michael G Doran; Ping Wang; Anna Patruno; Yilin Zhao; Deyou Zheng; Nikolaus Schultz; Charles L Sawyers
Journal:  Nature       Date:  2017-06-14       Impact factor: 49.962

4.  Coordinated Regulation of Cap-Dependent Translation and MicroRNA Function by Convergent Signaling Pathways.

Authors:  Scott H Olejniczak; Gaspare La Rocca; Megan R Radler; Shawn M Egan; Qing Xiang; Ralph Garippa; Craig B Thompson
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

Review 5.  In vivo RNAi screens: concepts and applications.

Authors:  Shane Crotty; Matthew E Pipkin
Journal:  Trends Immunol       Date:  2015-04-27       Impact factor: 16.687

6.  Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Authors:  Zhiqiang Li; Pedram Razavi; Qing Li; Weiyi Toy; Bo Liu; Christina Ping; Wilson Hsieh; Francisco Sanchez-Vega; David N Brown; Arnaud F Da Cruz Paula; Luc Morris; Pier Selenica; Emily Eichenberger; Ronglai Shen; Nikolaus Schultz; Neal Rosen; Maurizio Scaltriti; Edi Brogi; Jose Baselga; Jorge S Reis-Filho; Sarat Chandarlapaty
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

7.  A computational algorithm to predict shRNA potency.

Authors:  Simon R V Knott; Ashley Maceli; Nicolas Erard; Kenneth Chang; Krista Marran; Xin Zhou; Assaf Gordon; Osama El Demerdash; Elvin Wagenblast; Sun Kim; Christof Fellmann; Gregory J Hannon
Journal:  Mol Cell       Date:  2014-11-26       Impact factor: 17.970

8.  Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.

Authors:  Kumar Nikhil; Lei Chang; Keith Viccaro; Max Jacobsen; Callista McGuire; Shakti R Satapathy; Michael Tandiary; Meaghan M Broman; Gregory Cresswell; Yizhou J He; George E Sandusky; Timothy L Ratliff; Dipanjan Chowdhury; Kavita Shah
Journal:  Cancer Lett       Date:  2019-02-01       Impact factor: 8.679

9.  Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization.

Authors:  Manuel Valiente; Karuna Ganesh; Ekrem Emrah Er; Yilong Zou; Saloni Agrawal; Jing Hu; Bailey Griscom; Marc Rosenblum; Adrienne Boire; Edi Brogi; Filippo G Giancotti; Melitta Schachner; Srinivas Malladi; Joan Massagué
Journal:  Nat Cell Biol       Date:  2018-07-23       Impact factor: 28.824

10.  Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Authors:  George Au-Yeung; Franziska Lang; Walid J Azar; Chris Mitchell; Kate E Jarman; Kurt Lackovic; Diar Aziz; Carleen Cullinane; Richard B Pearson; Linda Mileshkin; Danny Rischin; Alison M Karst; Ronny Drapkin; Dariush Etemadmoghadam; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.